GlassScriptPhysician profile
Ching Yin Lam
NPI 1487640900
$1,770.00
in general payments reported to CMS, 2019-2025
11 companies · $105 in 2025
The $105 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,066 · 2020: $164 · 2021: $159 · 2022: $142 · 2023: $29.03 · 2024: $105 · 2025: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $239.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $463.22 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $430.85 | 2019 | |
| Abbvie INC. | $300.93 | 2019-2022 | |
| Glaxosmithkline, LLC. | $169.36 | 2019-2025 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $117.34 | 2019 | |
| Amgen INC. | $98.67 | 2023-2024 | Otezla, Repatha |
| Seqirus USA INC | $68.92 | 2024-2025 | Fluad, Flucelvax |
| Astrazeneca Pharmaceuticals LP | $61.64 | 2019-2024 | Breztri |
| Merck Sharp & Dohme LLC | $24.82 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $22.54 | 2019 | |
| Lilly USA, LLC | $11.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ching Yin Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.